TRPC6 Attenuates Cortical Astrocytic Apoptosis and Inflammation in Cerebral Ischemic/Reperfusion Injury

Lu Liu†, Manli Chen†, Kun Lin†, Xuwu Xiang†, Jing Yang†, Yueying Zheng†, Xiaoxing Xiong1,2* and Shengmei Zhu1*

1 Department of Anesthesiology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China,
2 Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, China

INTRODUCTION

The transient receptor potential (TRP) channels are cation-permeable membrane proteins with common structural features of six transmembrane segments. Based on the homology of amino acid sequences, the TRP superfamily can be subdivided into seven subfamilies: TRPC (canonical), TRPV (vanilloid), TRPM (melastatin), TRPA (ankyrin), TRPN (Drosophila NOMPC), TRPP (polycystin), and TRPML (mucolipin) (Venkatachalam and Montell, 2007). Among the channels, the TRPC channel, which is most closely related to Drosophila TRPs, is widely distributed in different tissues.
and governs the fate and functions of various cell types (Curcic et al., 2019). TRPCs are broadly expressed in brain, lung, heart, kidney, liver, spleen, and other organs in mammalian animals like human, mouse, rat, and rabbit (Montell, 2001; Venkatarachalam and Montell, 2007). In terms of similarity to amino acid sequences and function, TRPC members can be further classified into four subgroups: TRPC1, TRPC2, TRPC4/5, and TRPC3/6/7 (Wang et al., 2020a).

The TRPC6 channel is emerging as an important target for the control of Ca\(^{2+}\) currents in a wide range of disorders, including immune-mediated diseases, pulmonary arterial hypertension, atherosclerosis, and central nervous system (CNS)-related diseases, such as autism spectrum disorders, glioma, depression, traumatic brain injuries, seizure, Alzheimer's disease, and ischemic stroke (Hamid and Newman, 2009; Ding et al., 2010; Du et al., 2010; Griesi-Oliveira et al., 2015; Kim and Kang, 2015; Zhang et al., 2015, 2016; Pochwat et al., 2018; Ramirez et al., 2018; Chen et al., 2019). TRPC6 is abundantly expressed in various anatomical regions of the CNS, such as the cerebellum, hippocampus, middle frontal gyrus, and cortex (Riccio et al., 2002; Du et al., 2010). As a regulator of Ca\(^{2+}\) influx, TRPC6 is involved in neuronal survival, synapse formation, neuronal nerve-growth-cone guidance, and sensory transduction (Li et al., 2005; Jia et al., 2007; Zhou et al., 2008; Quick et al., 2012). Dysfunction of the TRPC6 channel may trigger a series of downstream events and neurobiological disorders.

Ischemic stroke is a life-threatening condition caused by a vascular embolism due to cardiac events, artery-to-artery embolism, or in-situ small artery disease (Hankey, 2017). Several underlying mechanisms, including excitotoxicity, ionic imbalance, oxidative and nitritative stress, inflammation, and apoptosis, are involved in the pathophysiological process of cerebral ischemia (Khoshnam et al., 2017). Ca\(^{2+}\) overload has a critical role and initiates the ischemic cascade during brain ischemia/reperfusion (IR) injury. Increasing evidence indicates an important role of TRPC6 in cerebral IR injury (Liu et al., 2020). TRPC6 is identified on cortical neurons and astrocytes, and is downregulated in neurons after brain ischemic injury (Du et al., 2010; Guo et al., 2017; Qu et al., 2017; Shirakawa et al., 2017). Notably, maintaining the TRPC6 protein level in neurons improves neuronal survival and behavioral performance, thus alleviating ischemic brain damage (Du et al., 2010; Guo et al., 2017). However, the roles of the TRPC6 channel in mouse cortical astrocytes following IR injury have not been evaluated.

In the present study, the specific effects of astrocytic TRPC6 on ischemic stroke were investigated. TRPC6 protein expression in primary mouse astrocytes was downregulated following IR injury. Inhibition of TRPC6 downregulation via HYP9 or TRPC6 overexpression protected astrocytes and the brain against IR insults. These results indicate that the TRPC6 channel contributes to neuroprotection in cerebral ischemia by promoting astrocyte survival. Furthermore, this study provides therapeutic evidence for the treatment of ischemic stroke by targeting the TRPC6 channel.

**MATERIALS AND METHODS**

**Animals**

C57BL/6J male mice 8–10 weeks of age were purchased from Shanghai SLAC Laboratory Animal Co., Ltd. (Shanghai, China). All animal experiments were approved by the Animal Care Committee of the First Affiliated Hospital at Zhejiang University. Mice were housed in polypropylene cages and maintained at 25 ± 1°C under 12 h light/12 h dark cycles with free access to rodent chow and water. Mice were randomly allocated to each group before any treatment. Proper anesthetic procedures were used to ensure that the mice did not suffer unnecessarily during or after the experimental procedure. A total of 82 mice were used in this study (including 10 mice that died).

**In vivo Model of Focal Cerebral Ischemia**

Focal cerebral ischemia was induced by middle cerebral artery occlusion (MCAO). Animals were anesthetized with 1% sodium pentobarbital (75–100 mg/kg, intraperitoneal injection); body temperature was maintained at 37 ± 0.5°C during the operation using a heating pad. Transient MCAO was generally performed as previously reported (Lin et al., 2013a). Briefly, the left common carotid artery was exposed to separate the internal carotid artery (ICA) and the external carotid artery (ECA). Next, a 6-0 monofilament nylon suture (RWD Life Science Co., LTD, Shenzhen, China) with a rounded tip was inserted through the exposed left ICA and advanced into the middle cerebral artery. After 1 h of occlusion, the filament was gently withdrawn to allow reperfusion. At 24 h after reperfusion, animals were sacrificed and the brain tissues were obtained for future assays.

**Intracerebroventricular Injection**

Mouse intracerebroventricular injection was performed using a stereotaxic instrument (RWD Life Science Co., LTD., Shenzhen, China) with a micro-syringe pump under anesthesia. Drugs or vehicle (5 µL in total) were slowly injected (1 µL/min) into the left ventricle at a depth of 2.5 mm below the brain surface, 1.0 mm lateral and 0.5 mm posterior to the bregma. After injection, animals were allowed to recover from anesthesia under a heating pad.

**Cell Culture**

As previously reported (Shen et al., 2016), primary astrocytes were isolated from cerebral cortices of 0–1-day-old post-natal C57BL/6 mice were isolated under sterile conditions. Astrocytes were grown in culture medium [Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal bovine serum and 1% penicillin/streptomycin]. Dissociated cortical cells were seeded onto poly-D-lysine (PDL, 10 µg/mL; # P7405; Sigma-Aldrich St. Louis, MO, USA)-coated T-75 flasks (Costar; Corning Inc., Corning, NY, USA) at a density of three cortices per flask and incubated at 37°C with 5% CO\(_2\) in a humidified incubator. The medium was changed every other day. After 8–10 days, confluent cultures were shaken (250 rpm at 37°C) for 12 h to reduce microglial contamination. Then, purified astrocytes were cultured in medium supplemented with 20 µM cytosine-1-β-D-arabinofuranosid (Sigma-Aldrich) for the next 2–3 days. The remaining attached cells were digested with 0.25% trypsin.
Oxygen-Glucose Deprivation and Re-oxygenation (OGD/R)

OGD/R experiments were established to mimic the in vitro condition of IR injury. The cultures were incubated for 1–4 h in DMEM medium without glucose in a humidified incubator chamber at 37°C with 95% N₂ and 5% CO₂. Subsequently, the astrocytes were returned to the original culture conditions and then incubated under normoxic conditions for the next 24 h.

Drugs and Experimental Groups

The TRPC6-specific agonist HYP9 (Leuner et al., 2010) (#H9791; Sigma-Aldrich), dissolved in dimethyl sulfoxide (DMSO; the final maximum DMSO concentration was <0.05%), was used to determine the role of TRPC6 in astrocytes following IR injury. To verify the optimum concentration, 0, 0.05, 0.5, 1, 5, 10, 15, 20, or 30 μM HYP9 was preincubated in vitro. SKF96365 (SKF; #ab120280; Abcam, Cambridge, MA, USA) was originally recognized as a major inhibitor of TRPC channels (Singh et al., 2010). In the present study, SKF (dissolved in deionized water) at 0, 0.05, 0.5, 1, 5, 10, 15, 20, or 40 μM concentration was used to treat primary mouse astrocytes. The in vitro groups consisted of eight subgroups: (1) control group (CON + Naive); (2) control combined with vehicle (DMSO) group (CON + Vehicle); (3) control combined with HYP9 (15 μM) group (CON + HYP9); (4) control combined with SKF (30 μM) group (CON + SKF); (5) OGD/R group (OGD + Naive); (6) OGD/R combined with vehicle (DMSO) group (OGD + Vehicle); (7) OGD/R combined with HYP9 (15 μM) group (OGD + HYP9); (8) OGD/R combined with SKF (30 μM) group (OGD + SKF).

Animals were randomly assigned into eight groups before any procedure as follows: (1) sham operation group (n = 9); (2) sham operation combined with vehicle (DMSO) group (n = 3); (3) sham operation combined with HYP9 (5 μg) group (n = 3); (4) sham operation combined with SKF (20 μg) group (n = 3); (5) MCAO operation group (n = 18); (6) MCAO operation combined with vehicle (DMSO) group (n = 12); (7) MCAO operation combined with HYP9 (5 μg) group (n = 12); (8) MCAO operation combined with SKF (20 μg) group (n = 12). The efficiency of infections was detected by western blotting.

Lentivirus Infection

Lentiviral vectors were chemically synthesized by Obio Technology (Shanghai) Corp., Ltd. To overexpress astrocytic TRPC6, we infected primary astrocytes with lentiviruses carrying FLAG-tagged full-length mCherry-WT-TRPC6 (WT-TRPC6) or mCherry-WT-TRPC6-null (Vehicle1). Besides, to knock down TRPC6 in primary astrocytes, lentiviruses carrying mCherry-shRNA-TRPC6 (sh-TRPC6) or mCherry-shRNA-TRPC6-null (Vehicle2) were used to infect primary cortical astrocytes. Targeted sequences for TRPC6 and Vehicle2 siRNAs are: GCTTGCCAAACATTGAGAAA and TTCTCCGAAAGTGTACGCT, respectively. Astrocytes at 70% confluence were infected with lentiviruses according to the vendor’s protocol. After 72–96 h lentiviral infection, astrocytes were used for subsequent experiments. The efficiency of infections was detected by western blots.

TTC Staining

Animals were sacrificed at 24 h after reperfusion. The infarct volume was tested based on 2,3,5-triphenyltetrazolium chloride (TTC) staining. The brains were sectioned into 2-mm coronal slices using a brain matrix. The brain slices were incubated in 2% TTC solution staining for 20 min at 37°C and then fixed in 4% paraformaldehyde (PFA). The ischemic volume was quantified using ImageJ software (version 2.0). The infarct percentage was shown as the ratio of the ischemic area to the entire slice area.

Analysis of Cell Viability and Lactate Dehydrogenase (LDH) Release

An LDH release quantification kit (#11644793001; Sigma-Aldrich) was used to evaluate cell viability. The cell-free supernatant was obtained by centrifugation at ~250 × g for 10 min. Subsequently, the supernatant was incubated in working solutions in the dark for 1 h at room temperature (~22°C). The absorbance of the samples was measured at 490 nm using a microplate reader (SpectraMax i3x; Molecular Devices, Sunnyvale, CA, USA). To determine the cytotoxicity percentage, all groups were compared with the control groups.

Flow Cytometry

The flow cytometry measurement of astrocyte apoptosis and Ca²⁺ concentration was performed using a BD flow cytometer (BD Biosciences, San Jose, CA, USA). Astrocytes were digested...
with trypsin. The harvested cells were washed with phosphate-buffered saline (PBS) twice before incubating in buffer containing 5 μL of fluorescein isothiocyanate-annexin V and 5 μL of propidium iodide or 0.5 μg/ml DAPI for 15 min at room temperature in the dark. Subsequently, the cells were detected and analyzed.

The Ca²⁺ concentration was also measured using the BD flow cytometer. Cortical astrocytes were loaded with 2 μM Fluo-4 AM (#F14217; Invitrogen, Carlsbad, CA, USA) in culture medium for 1 h at 37°C in an incubator with 5% CO₂. Next, the medium was changed to Hank’s balanced salt solution (#1425092; Gibco) and the astrocytes were incubated for another 30 min at 37°C. Then, the astrocytes were collected and analyzed using flow cytometry.

Western Blot
Western blot analysis was performed as previously described (Li et al., 2020). Samples (20–40 μg) were separated on 12% gels and transferred onto 0.45-μm polyvinylidene difluoride membranes (#IPVH00010; Millipore, Billerica, MA, USA). Membranes were blocked with 5% skim milk for 1 h and then incubated with the following primary antibodies at 4°C overnight: TRPC6 (1:1,000; #21403; SAB Biotherapeutics, Sioux Falls, SD, USA), caspase-3 (1:1,000; #ab214430; Abcam, Cambridge, MA, USA), NF-κB (1:1,000; #6956S; Cell Signaling Technology), phospho-NF-κB (1:1,000; #3033S, Cell Signaling Technology), IL-1β (1:2,000; #ab9722; Abcam), Flag (1:1,000; # F1804, Sigma-Aldrich), β-actin (1:2,000; #60008-1-Ig; Proteintech, Rosemont, IL, USA). Then, the membranes were incubated for 1 h with secondary antibodies (1:8,000; #SA00001-1 and #SA00001-2; Proteintech). Protein-specific signals were visualized using the Bio-Rad ChemiDoc™ MP imaging system (Hercules, CA, USA).

Immunofluorescence
Brain tissues were cut into 20-μm slices using a cryostat (#CM1950; Leica, Wetzlar, Germany). Tissues were blocked in 5% goat serum containing 0.3% Triton X-100 for 1 h at 37°C and then incubated with the following primary antibodies overnight at 4°C: GFAP (1:400; #80788S and #3670S; Cell Signaling Technology), TRPC6 (1:100; #ab62461; Abcam). Next, the slices were washed with PBS and incubated with secondary fluorescent antibodies (1:100; #SA00013-1, SA00013-2, SA00013-3, or SA00013-4; Proteintech) for 1 h at room temperature. In addition, 4',6-diamidino-2-phenylindole, dihydrochloride (DAPI; 1 μg/mL; #4083; Cell Signaling Technology) staining was used to visualize the nuclei. Images were acquired using a confocal laser-scanning microscope (Nikon A1 Ti, 600× magnification; Leica TCS SP8, 400× magnification).

Astrocytes plated on glass coverslips 12 mm in diameter were collected and fixed in 4% PFA for 15 min at room temperature. Subsequently, the fixed cells were permeabilized with 0.1% Triton X-100 for 15 min at room temperature followed by blocking in 10% goat serum at 37°C for 30 min. Before incubation with secondary fluorescent antibodies, the astrocytes were labeled with the following primary antibodies: GFAP (1:400; #80788S and #3670S; Cell Signaling Technology), NF-κB (1:100; #6956S; Cell Signaling Technology). Next, DAPI (1 μg/mL) was used to stain nuclei. Specific fluorescent signals were tested using a confocal microscope (Leica TCS SP8, 630× or 1,890× magnification).

Enzyme-Linked Immunosorbent Assay
The release of interleukin-6 (IL-6) and IL-1β from cortices and cultured astrocytes was quantified using enzyme-linked immunosorbent assay (IL-6, #70-EK206HS; IL-1β, #70-EK201BHS-96; MULTI SCIENCES, Hangzhou, China). The experiments were performed according to the manufacturer’s instructions. The final absorbance was detected at 450 nm and the background correction was set at 570 nm on a microplate reader (SpectraMax i3x; Molecular Devices).

Statistical Analyses
Data are presented as the mean ± standard error of the mean (SEM) of at least three independent analyses. SPSS ver. 25.0 software (IBM Corp., Armonk, NY, USA) and GraphPad Prism 8.0 software (GraphPad Software, San Diego, CA, USA) were used for statistical analyses. One-way analysis of variance with Tukey’s test for post-hoc analysis were performed. P-value <0.05 was considered statistically significant.

RESULTS
TRPC6 in Mouse Cortical Astrocytes Is Downregulated After Ischemia
In several studies, TRPC6 in neurons reportedly declines after cerebral ischemia, and maintaining the expression of neuronal TRPC6 protein contributes to neuronal survival and reduced cerebral ischemic insult (Du et al., 2010; Lin et al., 2013a; Guo et al., 2017). However, the role of the astrocytic TRPC6 channel after stroke remains unclear.

Astrocytes have provided important insights into ischemic stroke (Liu and Chopp, 2016). To confirm the vital functions of the astrocytic TRPC6 channel in cerebral ischemia, we established an in vitro model of stroke in primary mouse astrocytes using an OGD/R experiment. Astrocytes were exposed to 1–4 h of OGD followed by 24 h reperfusion. The apoptosis rate was elevated and cell viability was decreased in astrocytes following hypoxia injury (Figures 2A–C). The TRPC6 protein levels in astrocytes after OGD/R were significantly downregulated (Figures 2D,F). Conversely, the expression of the apoptosis-specific biomarker, cleaved caspase-3, was gradually increased after stroke compared with the control groups (Figures 2D,E). As shown in Figures 2A–D, 3 h OGD and 24 h reperfusion triggered appropriate hypoxic damage in astrocytes; thus, the subsequent in vitro OGD/R experiments were performed under this condition.

The in vivo stroke model is mimicked by MCAO in mice. Immunofluorescence signals showed that astrocytic TRPC6 was downregulated in the ischemic penumbra (Figures 2G,H). In parallel with the in vitro results, the TRPC6 protein level in peri-infarct areas was decreased compared with that in contralateral cortices (Figures 2I,K). In addition, after ischemic stroke, the cleaved caspase-3 expression in the ipsilateral hemisphere was upregulated compared with the contralateral hemisphere (Figures 2I,J). Furthermore, immunofluorescence
FIGURE 2 | TRPC6 in the cortical astrocytes is downregulated in ischemia. (A) Cultured astrocytes were exposed or not to OGD/R, and their apoptosis and death was detected by FITC/PI flow cytometry analysis. The percentage of apoptosis in scatter plots was presented as the proportion of apoptotic cells vs. total cell population. (Continued)
signals showed that astrocytic TRPC6 was downregulated in the ischemic penumbra (Figure 2H).

These results indicate that IR injury-induced changes in TRPC6 channel protein levels may have important functions in brain ischemia.

Reducing IR-Mediated TRPC6 Downregulation With HYP9 Alleviates Ischemic Insults in the Mouse Cortex

Consequently, to determine the role of TRPC6 in an in vivo model of ischemic stroke, intraventricular administration of HYP9 or SKF was performed in mice. MCAO resulted in increased infarct size and pro-inflammatory cytokine release compared with the sham groups (Figure 3). Pretreatment with HYP9 alleviated cortical injury, reduced infarct volume (Figures 3A,B), astrocytic population (Figure 3C), cleaved caspase-3 expression (Figures 3D,E), and inhibited pro-inflammatory cytokine (IL-6 and IL-1β) generation after MCAO (Figures 3G,H). However, the effects of SKF on an animal model of stroke regarding infarction volume, astrocytic population, cleaved caspase-3 protein level, and cytokine generation were not significantly different. In conclusion, the results show that application of the TRPC6 agonist HYP9 can alleviate IR-induced cerebral injury in an animal model of stroke.

Dose-Dependent HYP9 Inhibition of TRPC6 Downregulation in Astrocytes Promotes Astrocyte Survival During IR Injury

HYP9 is a specific TRPC6 channel activator (Leuner et al., 2010). Treatment with HYP9 (0, 1, 5, 10, 15, 20, or 30 µM) was used to verify whether TRPC6 channel degradation is responsible for IR-induced astrocytic insults. Astrocytes were pre-incubated with different concentrations of HYP9 for 12 h in a CO₂ chamber and then exposed to normal or OGD/R conditions. Application of 15 µM HYP9 contributed to a significant decrease in OGD/R-induced astrocyte apoptosis and cytotoxicity (Figures 4A–C). Western blot results showed that HYP9 (15 µM) suppressed the downregulation of TRPC6 and decreased cleaved caspase-3 protein levels in primary mouse astrocytes in the OGD group (Figures 4D–F). These results indicate that maintaining the protein level of the TRPC6 channel in astrocytes with HYP9 diminishes OGD/R-induced astrocyte apoptosis and improves cell vitality.

TRPC Antagonist SKF Aggravates Astrocyte Damage Dose-Dependently in the OGD/R Experiment

Next, whether blockage of the TRPC6 channel by SKF results in increased astrocyte damage after OGD/R was investigated. Cultured astrocytes were pretreated with 0, 0.05, 0.5, 5, 10, 20, 30, or 40 µM SKF for 12 h before the OGD/R experiment. As shown in Figures 5A,B, the apoptosis of astrocytes was markedly increased in the OGD group supplemented with 30 or 40 µM SKF compared with the OGD group without SKF pretreatment. In addition, the effects of SKF on astrocyte cytotoxicity in the control and OGD groups were investigated using the LDH assay. Notably, IR injury-mediated astrocyte cytotoxicity was elevated after pre-incubation with 20, 30, or 40 µM SKF in OGD groups (Figure 5C). In addition to the increased cleaved caspase-3 expression, the OGD/R-induced degradation of TRPC6 protein was not rescued after treatment with SKF (Figures 5D–F). Taken together, pretreatment of cultured astrocytes with 30 or 40 µM SKF aggravates apoptosis and cytotoxicity in OGD groups.

TRPC6 Protects Astrocytes Against IR Injury in Modeled Ischemia

To further clarify the protective role of astrocytic TRPC6 during IR injury, we then infected primary cortical astrocytes with lentivirus vectors to overexpress (WT-TRPC6) or knock down (sh-TRPC6) TRPC6. The efficiency of lentiviral infections was shown in Figure 6D. OGD/R notably decreased the protein levels of TRPC6 compared with that in control groups in astrocytes (Figure 6D). Overexpression of TRPC6 strikingly reduced OGD/R-induced astrocyte apoptosis (Figures 6A,B), cytotoxicity (Figure 6C), and cleaved caspase-3 protein levels (Figures 6D,E). However, knocking down TRPC6 via sh-TRPC6 did not exacerbate IR injury-mediated apoptosis, cytotoxicity or cleaved caspase-3 protein levels in astrocytes (Figure 6). In general, TRPC6 attenuates astrocytes IR injury in modeled ischemia in vitro.

Maintaining the Protein Level of the TRPC6 Channel in Astrocytes Alleviates Astrocytic Inflammatory Responses

Astrocytic inflammatory response also has a critical effect on regulating the progress and prognosis of ischemic stroke (Cekanaviciute and Buckwalter, 2016; Deng et al., 2018). In
Reducing IR-mediated TRPC6 downregulation with HYP9 alleviates ischemic damage in mice. Vehicle (DMSO), 5 µg HYP9, or 20 µg SKF were injected into left ventricles of mice 24 h before sham or MCAO operation. (A) TTC-stained cerebral slices indicated the infarct size in mice. (B) Quantification of infarct volumes after ischemia. Data were shown as mean ± SEM (n = 3). #p < 0.05 vs. MCAO + Naive group. (C) Representative images of astrocytes population with GFAP (green) staining in contralateral or peri-infarct cortices in MCAO mice (Scar bar: 100 µm; 400× magnification). (D) Western blot detecting TRPC6 and cleaved caspase-3 in mouse cortices. β-actin was used as a loading control. (E,F) Quantifications of cleaved caspase-3 and TRPC6 protein levels shown in (D). Data were
FIGURE 3 | The release of IL-6 and IL-1β was determined by ELISA assay. Data were shown as mean ± SEM (n = 3). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 vs. MCAO + Naïve group in contralateral cortices; #p < 0.05, ##p < 0.01 vs. MCAO + Naïve group in peri-infarct area.

FIGURE 4 | Inhibition of TRPC6 downregulation by HYP9 protects astrocytes from ischemic damage. Astrocytes were pre-incubated with 0, 1, 5, 10, 15, 20, and 30 µM HYP9 for 12 h, and then subjected to control condition (CON) or 3 h OGD and 24 h reperfusion (OGD). (A) Representative scatter plots of astrocytic apoptosis measured by Annexin-V FITC/PI flow cytometry in each group. (B) Cell apoptosis rate was analyzed by Annexin-V FITC/PI flow cytometry, and the data were shown as mean ± SEM (n = 4). (C) Quantification of OGD/R-mediated cell cytotoxicity by LDH assay. Data were shown as mean ± SEM (n = 4). (D) Immunoblots for TRPC6 and cleaved caspase-3 of the extracts from CON or OGD-treated cortical astrocytes acquiring 15 µM HYP9 or not. β-actin was used as a loading control. (E,F) Quantifications of cleaved caspase-3 and TRPC6 protein levels shown in (D). Data were shown as mean ± SEM (n = 3). *p < 0.05, **p < 0.01, ***p < 0.001 vs. CON (HYP9 = 0 µM) group; #p < 0.05, ###p < 0.001, ####p < 0.0001 vs. OGD (HYP9 = 0 µM) group.
FIGURE 5 | TRPC antagonist SKF aggravates OGD/R induced astrocytes insults. Astrocytes were pre-incubated with 0, 0.05, 0.5, 5, 10, 20, 30, and 40 µM SKF for 12 h, and then subjected to control condition (CON) or 3 h OGD and 24 h reperfusion (OGD). (A) Representative scatter plots of astrocytic apoptosis measured by Annexin-V FITC/PI flow cytometry in each group. (B) Cell apoptosis rate was analyzed by Annexin-V FITC/PI flow cytometry, and the data were shown as mean ± SEM (n = 4). (C) Quantification of OGD/R-mediated cell cytotoxicity by LDH assay. Data were shown as mean ± SEM (n = 4). (D) Immunoblots for TRPC6 and cleaved caspase-3 of the extracts from CON or OGD-treated cortical astrocytes acquiring 30 µM SKF or not. β-actin was used as a loading control. (E,F) Quantifications of cleaved caspase-3 and TRPC6 protein levels shown in (D). Data were shown as mean ± SEM (n = 3). **p < 0.01, ***p < 0.001, ****p < 0.0001 vs. CON (SKF = 0 µM) group; #p < 0.05, ###p < 0.01, ####p < 0.0001 vs. OGD (SKF = 0 µM) group.
FIGURE 6 | TRPC6 protects astrocytes against IR injury in modeled ischemia. Astrocytes were infected with lentiviruses carrying mCherry-WT-TRPC6-null (Vehicle1), FLAG-tagged full-length mCherry-WT-TRPC6 (WT-TRPC6), mCherry-shRNA-TRPC6-null (Vehicle2), or mCherry-shRNA-TRPC6 (sh-TRPC6), and then exposed to control condition (CON) or 3 h OGD and 24 h reperfusion (OGD). (A) Representative scatter plots of astrocytic apoptosis measured by Annexin-V FITC/DAPI flow cytometry in each group. (B) Cell apoptosis rate was analyzed by Annexin-V FITC/DAPI flow cytometry, and the data were shown as mean ± SEM (n = 4). (C) Quantification of OGD/R-mediated cell cytotoxicity by LDH assay. Data were shown as mean ± SEM (n = 4). (D) Immunoblots for Flag, TRPC6, and cleaved caspase-3 of the extracts from control or OGD-treated cortical astrocytes acquiring Vehicle1, WT-TRPC6, Vehicle2, or sh-TRPC6 vectors. β-actin was used as a loading control. (E) Quantification of cleaved caspase-3 protein levels shown in (D). Data were shown as mean ± SEM (n = 3). *p < 0.05, **p < 0.01, ***p < 0.001 vs. CON + naive group; ###p < 0.001, ####p < 0.0001 vs. OGD + naive or OGD + Vehicle1 group.
addition to cell apoptosis and vitality, the expression of the pro-inflammatory cytokines IL-6 and IL-1β were measured to confirm the effects of HYP9 and SKF on ischemic astrocytic inflammation. The IL-6 and IL-1β protein levels were significantly increased in the OGD groups compared with the control groups. Notably, HYP9 and WT-TRPC6 reduced the elevated level of IL-6 and IL-1β in astrocytes in the OGD groups (Figures 7A–F).

The data show that inhibition of TRPC6 downregulation with HYP9 or WT-TRPC6 reduces inflammatory responses in astrocytes after OGD/R.

Inhibiting TRPC6 Downregulation Suppresses Intracellular Ca<sup>2+</sup> Overload in Primary Astrocytes

The above reported results indicate the TRPC6 channel is closely associated with apoptosis, vitality, and inflammatory response in cultured cortical astrocytes exposed to IR damage. As a Ca<sup>2+</sup> channel, TRPC6 modulates the concentration of intracellular Ca<sup>2+</sup> ([Ca<sup>2+</sup>]), which is closely involved in ischemic stroke (Pekny et al., 2016; Werner et al., 2020). Astrocytes interact with neurons and participate in structural support, neuronal metabolism, synaptogenesis, synaptic transmission, axonal remodeling, and neurogenesis (Halassa and Haydon, 2010; Liu and Chopp, 2016). IR injury-activated astrocytes initiate the CNS inflammatory response, which in turn exacerbates brain insults during ischemic stroke (Cekanaviciute and Buckwalter, 2016). Thus, maintaining the normal function of astrocytes likely promotes post-ischemic neurological recovery. Therapeutic targeting of astrocytes is expected to be a future area of research regarding treatment and prognosis of brain ischemia (Neuhaus et al., 2017).

Evidence shows that TRPC6 is a crucial regulator of inflammatory cascades, especially in pulmonary inflammation (Chen et al., 2020; Ortiz-Muñoz et al., 2020). TRPC6 contributes to platelet activation, leukocyte transendothelial migration, lung vascular barrier disruption, and airway inflammation (Tauseef et al., 2012; Weber et al., 2015; Chen et al., 2020; Ortiz-Muñoz et al., 2020). In addition, activation of the TRPC6 channel promotes apoptosis in neonatal glomerular mesangial cells and renal tubular epithelial cells under different injury conditions (Soni and Adebiyi, 2016; Hou et al., 2018). TRPC6 inhibits N-methyl-D-aspartate (NMDA)-mediated Ca<sup>2+</sup> elevation and reduces neuronal ischemic excitotoxicity (Li et al., 2012). Furthermore, inhibition of TRPC6 degradation in neurons through cAMP-response element binding protein (CREB) pathway alleviates ischemic cerebral insults (Du et al., 2010). (-)-Epigallocatechin-3-gallate, resveratrol, and neuroprotectin D1 contribute to neuroprotective effect on brain IR damage through TRPC6/CREB pathways (Lin et al., 2013b; Yao et al., 2013, 2014). In particular, Hyperforin, a selective TRPC6 agonist, alleviates cerebral IR injury by suppressing the degradation of TRPC6 and increasing phosphorylated CREB in Ca<sup>2+</sup>/calmodulin-dependent kinase IV (CaMKIV) signaling pathway (Lin et al., 2013a).

DISCUSSION

In cerebral ischemia, several clinical trials have failed due to narrow therapeutic window, adverse effects, and individual differences (Petrovic-Djergovic et al., 2016). A breakthrough in stroke therapeutic strategies is considered urgent. In the present study, significant downregulation of TRPC6 protein was observed in both cultured astrocytes and cerebral cortices after IR injury. In vivo results confirmed that the TRPC6 channel-specific activator HYP9 attenuated the infarct volume, astrocytes population, apoptosis, and the generation of pro-inflammatory cytokines (IL-6 and IL-1β) caused by MCAO. However, significant effects of SKF on infarct lesion or cortical IL-6 and IL-1β release in MCAO mice were not observed. In addition, HYP9 was shown to attenuate apoptosis rate, improve cell vitality, and reduce the generation of IL-6 and IL-1β in cultured astrocytes subjected to OGD/R. Furthermore, the TRPC channel antagonist SKF aggravated astrocytic apoptosis and cytokotoxicity in OGD groups. In addition, inhibition of the TRPC6 channel downregulation with HYP9 suppressed the increase in [Ca<sup>2+</sup>] in ischemic astrocytes. The IR-mediated increased NF-κB phosphorylation and nuclear translocation were inhibited by HYP9 pretreatment in primary mouse astrocytes. In parallel, overexpression of TRPC6 also decreased IR injury-induced astrocytic apoptosis, cytotoxicity, inflammatory responses and NF-κB phosphorylation in modeled ischemia in vitro.

Previously, neuron-specific-related mechanisms are primarily considered in the pathogenesis of brain ischemia. As knowledge increased, astrocytes and other CNS cells are shown to be closely involved in ischemic stroke (Pekny et al., 2016; Werner et al., 2020). Astrocytes interact with neurons and participate in structural support, neuronal metabolism, synaptogenesis, synaptic transmission, axonal remodeling, and neurogenesis (Halassa and Haydon, 2010; Liu and Chopp, 2016). IR injury-activated astrocytes initiate the CNS inflammatory response, which in turn exacerbates brain insults during ischemic stroke (Cekanaviciute and Buckwalter, 2016). Thus, maintaining the normal function of astrocytes likely promotes post-ischemic neurological recovery. Therapeutic targeting of astrocytes is expected to be a future area of research regarding treatment and prognosis of brain ischemia (Neuhaus et al., 2017).
FIGURE 7 | Maintaining the protein level of TRPC6 attenuates astrocytic inflammatory responses. Astrocytes were pre-incubated with DMSO (as vehicle, the final DMSO concentration was 0.025%), 15 µM HYP9 or 30 µM SKF for 12 h, and then exposed to control condition (CON) or 3 h OGD and 24 h reperfusion (OGD). (A) The protein level of IL-6 was determined by ELISA assay. Data were shown as mean ± SEM (n = 4). (B) The expression of pro-inflammatory cytokine IL-1β in cortical astrocytes was measured using western blotting. β-actin was used as a loading control. (C) Quantification of IL-1β protein levels shown in (B). Data were shown as mean ± SEM (n = 4). (E) The expression of pro-inflammatory cytokine IL-1β in cortical astrocytes was measured using western blotting. β-actin was used as a loading control. (F) Quantification of IL-1β protein levels shown in (E). Data were shown as mean ± SEM (n = 3). **p < 0.01, ***p < 0.001, ****p < 0.0001 vs. CON + Naive group; #p < 0.05, ####p < 0.0001 vs. OGD + Naive or OGD + Vehicle1 group.

Evidences suggest the vital role of TRPC6/CREB pathway in ischemic stroke. Studies have shown that TRPC6 channel is expressed in microglia and involved in microglial activation and neuroinflammatory response in different diseases including hypertension, epilepsy, Alzheimer's disease, infectious diseases and neuropathic pain (Toth et al., 2013; Lee et al., 2014; Liu et al., 2017; Shinjyo et al., 2020; Wang et al., 2020b). However, the relevance of the TRPC6 channel in IR injury-induced astrocytic apoptosis and inflammation remains unclear. In addition, other downstream mechanisms beyond TRCP6/CREB pathways are worth exploring.

Hyperforin, a main compound of St. John's wort, can activate the TRPC6 channel and induce changes in [Ca^{2+}]_i currents (Leuner et al., 2007); however, hyperforin is chemically unstable when subjected to oxygen and light. HYP9 is a stable synthetic phloroglucinol derivative of hyperforin that maintains the biological function of hyperforin in activating the TRPC6 channel (Leuner et al., 2010). Consequently, HYP9 was used in the present study to explore its function in the TRPC6 channel and the associated downstream cellular mechanisms in ischemic stroke. Inflammatory responses and apoptosis in ischemic astrocytes were inhibited by maintaining the protein level of the TRPC6 channel via HYP9. Overexpression of TRPC6 also reduced IR injury-induced astrocytic apoptosis, cytotoxicity, and inflammatory responses in experimental stroke in vitro. Meanwhile, SKF is a TRPC channel blocker (Song et al., 2014; Jing et al., 2016). SKF also affects other channels belonging to the TRPC channel subfamily. Evidence shows that TRPC1, TRPC3,
and TRPC7 are involved in cerebral ischemic stroke (Chen et al., 2017; Xu et al., 2018). In the present study, SKF aggravated astrocyte injury after ischemia in vitro. However, significant changes in infarct volume, cleaved caspase-3 expression, and cytokine release were not observed in the MCAO model after SKF application. The inconsistent results between cell and animal models of stroke may be due to the complex effects of SKF on cortical non-astrocytic cells. Noticeably, knocking down TRPC6 via sh-TRPC6 shown no significant effects on SKF application. The inconsistent results between cell and physiological changes. Modulation of the Ca$^{2+}$ current has attracted interest as a promising medical strategy for ischemic stroke (Kalogeris et al., 2016; Secondo et al., 2018). The TRPC6 channel, a Ca$^{2+}$ permeable cation channel, has been associated with Ca$^{2+}$ entry and brain ischemic pathogenesis (Liu et al., 2020). In the present study, TRPC6 was dramatically downregulated during IR injury. The TRPC6-specific agonist HYP9 rescued TRPC6 degradation in primary cultured astrocytes and reduced [Ca$^{2+}$]$_i$. Consistently, the TRPC channel antagonist SKF contributed to increased [Ca$^{2+}$]$_i$. How a Ca$^{2+}$ entry activator reduces and a Ca$^{2+}$ channel blocker increases the Ca$^{2+}$ influx in primary astrocytes is notable. TRPC6 has been shown to block the NMDA receptor (NMDAR)-triggered [Ca$^{2+}$]$_i$ increase and neurotoxicity in neurons after brain IR damage (Li et al., 2012). Overexpression of TRPC6 inhibits [Ca$^{2+}$]$_i$ overload, prevents neuronal death, lessens infarct size, and improves behavior performance after ischemia. Similarly, another research team suggests that the TRPC6 channel selectively suppresses the NMDAR-mediated current in hippocampal neurons, which is increased via TRPC6 knockdown or interference with SKF (Shen et al., 2013). In another study, SKF increases intracellular Ca$^{2+}$ by promoting the reverse mode of the Na$^+/Ca^{2+}$ exchanger (Song et al., 2014). Thus, we hypothesized that the underlying mechanism of TRPC6-induced [Ca$^{2+}$]$_i$ decrease in astrocytes after ischemic insults may be associated with the complex interaction between the TRPC6 channel and other ion exchangers.

Although the present study showed a protective role of the TRPC6 channel in astrocytes after ischemia, various questions remain unanswered. The effects of the astrocytic TRPC6

![Image](image-url)
FIGURE 9 | TRPC6 diminishes NF-κB nuclear translocation in astrocytes after ischemia. Astrocytes were pre-incubated with Vehicle (DMSO, the final concentration is 0.025%), 15 μM HYP9 or 30 μM SKF for 12 h, and then expose to control condition (CON) or 3 h OGD and 24 h reperfusion (OGD). Representative images of cortical astrocytes after OGD/R double-stained with the NF-κB (red) and GFAP (green) antibodies (Scar bar: 100 μm; 630× or 1,890× magnification).

channel on ischemic neurons will be addressed in our future work. Furthermore, the underlying mechanisms of TRPC6-triggered astrocytic Ca\(^{2+}\) changes in ischemic stroke warrant further investigations.

CONCLUSION

The results of the present study indicate that HYP9 reduces the infarct size, apoptosis, and pro-inflammatory cytokine release in
Liu et al. TRPC6 Attenuates Ischemic Brain Damage

**FIGURE 10** | TRPC6 diminishes OGD/R-induced NF-κB phosphorylation in astrocytes. Astrocytes were pre-incubated with Vehicle (DMSO, the final concentration is 0.025%), 15 μM HYP9 or 30 μM SKF for 12 h, and then expose to control condition (CON) or 3 h OGD and 24 h reperfusion (OGD). (A) Immunoblots for TRPC6, NF-κB, and phosphorylated-NF-κB (P-NF-κB) of the extracts from cortical astrocytes. β-actin was used as a loading control. (B–D) Quantification of TRPC6, NF-κB, and P-NF-κB protein levels shown in (A). Data were shown as mean ± SEM (n = 3). Astrocytes were infected with lentiviruses carrying Vehicle1, WT-TRPC6, Vehicle2, or sh-TRPC6, and then exposed to control condition (CON) or 3 h OGD and 24 h reperfusion (OGD). (E) Immunoblots for NF-κB and P-NF-κB of the extracts from cortical astrocytes. β-actin was used as a loading control. (F,G) Quantification of NF-κB, and P-NF-κB protein levels shown in (E). Data were shown as mean ± SEM (n = 3). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 vs. CON + Naive group; #p < 0.05, ##p < 0.01, ###p < 0.001, ####p < 0.0001 vs. OGD + Naive or OGD + Vehicle1 group.

a mouse model of ischemic stroke. Inhibition of TRPC6 channel downregulation via HYP9 or TRPC6 overexpression alleviates apoptosis and inflammatory response in astrocytes exposed to ischemic damage. Furthermore, the protective role of TRPC6 in stroke is associated with Ca^{2+}/NF-κB-dependent pathways. The results of this study indicate that the astrocytic TRPC6 channel and TRPC6 agonist HYP9 might be a novel therapeutic approach to prevent ischemic stroke induced by brain injury.
DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/supplementary materials, further inquiries can be directed to the corresponding author/s.

ETHICS STATEMENT

The animal study was reviewed and approved by Animal Care Committee of the First Affiliated Hospital at Zhejiang University.

REFERENCES

Bai, X., Zhang, Y. L., and Liu, L. N. (2020). Inhibition of TRIM8 restrains ischaemia-reperfusion-mediated cerebral injury by regulation of NF-κB activation associated inflammation and apoptosis. Exp. Cell Res. 388:111818. doi: 10.1016/j.yexcr.2020.111818

Berry, C. T., May, M. J., and Freedman, B. D. (2018). STIM- and Orai-mediated calcium entry controls NF-κB activity and function in lymphocytes. Cell Calcium 74, 131–143. doi: 10.1016/j.ceca.2018.07.003

Cekanaviciute, E., and Buckwalter, M. S. (2016). Astrocytes: integrative regulators of neuroinflammation in stroke and other neurological diseases. Neurotherapeutics 13, 685–701. doi: 10.1007/s13311-016-0477-8

Chen, Q., Zhou, Y., Zhou, L., Fu, Z., Yang, C., Zhao, L., et al. (2020). Essential role of TRPC6 in ischemic brain damage. J. Neurochem. 120, 3480–3492. doi: 10.1111/jn.15315

Ding, X., He, Z., Zhou, K., Cheng, J., Yao, H., and Wang, Y. (2010). Ap-1 (activated protein-1) transcription factor JunD regulates ischemia/reperfusion brain damage via IL-1β (interleukin-1β). Stroke 50, 469–477. doi: 10.1161/strokeaha.110.023739

Ding, X., He, Z., Zhou, K., Cheng, J., Yao, H., Lu, D., et al. (2010). Essential role of TRPC6 channels in G2/M phase transition and development of human gloma. J. Natl. Cancer Inst. 102, 1052–1069. doi: 10.1093/jnci/djg217

Du, W., Huang, J., Yao, H., Zhou, K., Duan, B., and Wang, Y. (2010). Inhibition of TRPC6 degradation suppresses ischemic brain damage in rats. J. Clin. Invest. 120, 3480–3492. doi: 10.1172/JCI45165

Gries-Oliveira, K., Acab, A., Gupta, A. R., Sunaga, D. Y., Chailangkarn, T., Nicol, X., et al. (2015). Modeling non-syndromic autism and the impact of TRPC6 disruption in human neurons. Mol. Psychiatry 20, 1350–1365. doi: 10.1038/mp.2014.141

Guo, C., Ma, Y., Ma, S., Mu, F., Deng, J., Duan, J., et al. (2017). The role of TRPC6 in the neuroprotection of calycosin against cerebral ischemic injury. Sci. Rep. 7:3039. doi: 10.1038/s41598-017-03404-6

Halassa, M. M., and Haydon, P. G. (2010). Integrated brain circuits: astrocytic networks modulate neuronal activity and behavior. Annu. Rev. Physiol. 72, 335–355. doi: 10.1146/annurev-physiol-021909-135843

Hamby, M. E., Coppola, G., Ao, Y., Geschwind, D. H., Khakh, B. S., and Sofroniew, M. V. (2012). Inflammatory mediators alter the astrocyte transcriptome and calcium signaling elicited by multiple G-protein-coupled receptors. J. Neurosci. 32, 14489–14510. doi: 10.1523/jneurosci.1256-12.2012

Hämírd, R., and Newman, J. H. (2009). Evidence for inflammatory signaling in idiopathic pulmonary artery hypertension: TRPC6 and nuclear factor-kappaB. Circulation 119, 2297–2298. doi: 10.1161/circulationaha.108.855197

Hankey, G. J. (2017). Stroke. Lancet 389, 641–654. doi: 10.1016/s0140-6736(16)30962-x

Hou, X., Xiao, H., Zhang, Y., Zeng, Y., Huang, M., Chen, X., et al. (2018). Transient receptor potential channel 6 knockdown prevents apoptosis of renal tubular epithelial cells upon oxidative stress via autophagy activation. Cell Death Dis. 9:1015. doi: 10.1038/s41419-018-1052-5

Jia, Y., Zhou, J., Tai, Y., and Wang, Y. (2007). TRPC6 inhibitor, lirilaryl acetate, is effective in protecting against traumatic brain injury via astrocyte apoptosis inhibition and effects on NF-κB translocation. Mol. Neurobiol. 34, 7555–7566. doi: 10.1007/s12035-013-0227-2

Yang, C., Zhao, L., Fu, Z., Yang, C., Zhou, L., et al. (2020). Essential role of TRPC6 in ischemic brain damage. J. Neurochem. 120, 3480–3492. doi: 10.1111/jn.15315

Kim, Y. J., and Kang, T. C. (2015). The role of TRPC6 in seizure susceptibility and seizure-related neuronal damage in the rat dentate gyrus. Neuroscience 307, 215–230. doi: 10.1016/j.neuroscience.2015.08.054

Kopitar-Jeral, N. (2015). Innate immune response in brain, NF-kappaB signaling and cytokins. Front. Mol. Neurosci. 8:73. doi: 10.3389/fnmol.2015.00073

Lee, S. K., Kim, J. E., Kim, Y. J., Kim, M. I., and Kang, T. C. (2014). Hyperforin attenuates microglia activation and inhibits p65-Ser276 NFκB phosphorylation in the rat piform cortex following status epilepticus. Neurosci. Res. 85, 39–50. doi: 10.1016/j.neures.2014.05.006

Leuner, K., Heiser, J. H., Derksien, S., Mladenov, M. I., Fehske, C. J., Schubert, R., et al. (2010). Simple 2,4-diacylphloroglucinols as classic transient receptor potential-6 activators–identification of a novel pharmacophore. Mol. Pharmacol. 77, 368–377. doi: 10.1124/mol.109.057513

Leuner, K., Kazanski, V., Müller, M., Eisin, K., Henke, B., Gollasch, M., et al. (2007). Hyperforin—a key constituent of St. John’s wort specifically activates TRPC6 channels. FEBS J. 21, 4011–4111. doi: 10.1111/j.1742-4658.2007.05860.x

Li, H., Huang, J., Du, W., Jia, C., Yao, H., and Wang, Y. (2012). TRPC6 inhibited NMDA receptor activation and protected neurons from ischemic excitotoxicity. J. Neurochem. 123, 1010–1018. doi: 10.1111/jnc.12045

Li, H., Xie, Y., Zhang, N., Yu, Y., Zhang, Q., and Ding, S. (2015). Disruption of IP3R2-mediated Ca2+ signaling pathway in astrocytes ameliorates neuronal inflammation in stroke and other neurological diseases. Neurotherapeutics 12, 131–143. doi: 10.1016/j.nurt.2014.10.003

AUTHOR CONTRIBUTIONS

LL wrote the manuscript. LL, MC, and KL finished the experiments. SZ and XXio designed the general idea. All authors edited the drafts of the manuscript.

FUNDING

This study was supported by the National Natural Science Foundation of China No. 81971008 to SZ and No. 81870939 to XXio.
death and brain damage while reducing behavioral deficits after focal ischemic stroke. *Cell Calcium* 58, 565–576. doi: 10.1016/j.ceca.2015.09.004

Li, Q., Cao, Y., Dang, C., Han, B., Han, R., Ma, H., et al. (2020). Inhibition of double-strand DNA-sensing cGAS ameliorates brain injury after ischemic stroke. *EMBO Mol. Med.* 12:e11002. doi: 10.15252/emmm.201911002

Li, Y., Jia, Y. C., Cui, K., Li, N., Zheng, Z. Y., Wang, Y. Z., et al. (2005). Essential role of TRPC channels in the guidance of nerve growth cones by brain-derived neurotrophic factor. *Nature* 434, 894–898. doi: 10.1038/nature03477

Lin, Y., Chen, F., Zhang, J., Wang, T., Wei, X., Wu, J., et al. (2013b). Neuroprotective effect of resveratrol on ischemia/reperfusion injury in rats through TRPC6/CREB pathways. *J. Mol. Neurosci.* 50, 504–513. doi: 10.1007/s12031-013-9977-8

Lin, Y., Zhang, J. C., Fu, J., Chen, F., Wang, J., Wu, Z. L., et al. (2013a). Hyperforin attenuates brain damage induced by transient middle cerebral artery occlusion (MCAO) in rats via inhibition of TRPC6 channels degradation. *J. Cereb. Blood Flow Metab.* 33, 253–262. doi: 10.1038/jcbfm.2012.164

Liu, H., Wu, X., Luo, J., Wang, X., Guo, H., Feng, D., et al. (2019). Pterostilbene attenuates astrocytic inflammation and neuronal oxidative injury after ischemia-reperfusion by inhibiting NF-κB phosphorylation. *Front. Immunol.* 10:2408. doi: 10.3389/fimmu.2019.02408

Liu, L., Gu, L., Chen, M., Zheng, Y., Xiong, X., and Zhu, S. (2020). Novel targets of cation channels. *Acta Neuropathol.* 139, 101–102. doi: 10.1007/s00401-020-02139-8

Montell, C. (2001). Physiology, phylogeny, and functions of the TRP superfamily of cation channels. *Sci. STKE* 2001:re1. doi: 10.1126/stke.2001.90.re1

Neuhaus, A. A., Couch, Y., Hadley, G., and Buchan, A. M. (2017). Neuroprotection of cation channels. *Front. Aging Neurosci.* 9:270. doi: 10.3389/tna.2017.00270

Pekny, M., Pekna, M., Messing, A., Steinhäuser, C., Lee, J. M., Parpura, V., et al. (2018). NF-κB-dependent up-regulation of TRPC6 by Aβ in BV-2 microglia cells increases COX-2 expression and contributes to hippocampus neuron damage. *Neurosci. Lett.* 651, 1–8. doi: 10.1016/j.neulet.2017.04.056

Riccio, A., Medhurst, A. D., Mattei, C., Kelsell, R. E., Calver, A. R., Randall, A. D., et al. (2002). mRNA distribution analysis of human TRPC family in CNS and peripheral tissues. *Brain Res. Mol. Brain Res.* 109, 95–104. doi: 10.1016/s0169-328x(02)00527-2

Shih, R. H., Wang, C. Y., and Yang, C. M. (2015). NF-kappaB signaling pathways in neurological inflammation: a mini review. *Front. Mol. Neurosci.* 8:77. doi: 10.3389/fnmol.2015.00077

Shinjiyo, N., Nakayama, H., Li, L., Ishimaru, K., Hikosaka, K., Suzuki, N., et al. (2020). Hypericum perforatum extract and hyperforin inhibit the growth of neurotrophic parasite *Toxoplasma gondii* and infection-induced inflammatory responses of glial cells in vitro. *J. Ethnopharmacol.* doi: 10.1016/j.jep.2020.113525. [Epub ahead of print].

Shirakawa, H., Katsumoto, R., Iida, S., Miyake, T., Higuchi, T., Nagashima, T., et al. (2017). Sphingosine-1-phosphate induces Ca2+-signaling and CXCL1 release via TRPC6 channel in astrocytes. *Glia* 65, 1005–1016. doi: 10.1002/glia.23141

Soni, H., and Adebiyi, A. (2016). TRPC6 channel activation promotes neonatal glomerular mesangial cell apoptosis via calcineurin/NFAT and Fas/FasL signaling pathways. *J. Cell Physiol.* 231, 323–345. doi: 10.1002/jcp.25249

Sorofinie, M. V. (2014). Multiple roles for astrocytes as effectors of cytokines and inflammatory mediators. *Neuroscientist.* 20, 160–172. doi: 10.1177/1073858413504466

Song, M., Chen, D., and Yu, S. P. (2014). The TRPC channel blocker SKF96365 inhibits glioblastoma cell growth by enhancing reverse mode of the Na(+)/Ca2+ exchanger and increasing intracellular Ca2+. *Br. J. Pharmacol.* 171, 3432–3447. doi: 10.1111/bph.12691

Soni, H., and Adelphi, A. (2016). TRPC6 channel activation promotes neonatal glomerular mesangial cell apoptosis via calcineurin/NFAT and Fas/FasL signaling pathways. *Sci. Rep.* 6:29041. doi: 10.1038/srep29041

Su, Y., Zong, S., Wei, C., Song, F., Feng, H., Qin, A., et al. (2019). Salidroside promotes rat spinal cord injury recovery by inhibiting inflammatory cytokine expression and NF-κB and MAPK signaling pathways. *J. Cell Physiol.* 234, 14259–14269. doi: 10.1002/jcp.28124

Tauseef, M., Knezevic, N., Chava, K. R., Smith, M., Sukriti, S., Gianaris, N., et al. (2012). TLR4 activation of TRPC6-dependent calcium signaling mediates endotoxin-induced lung vascular permeability and inflammation. *J. Exp. Med.* 209, 1953–1968. doi: 10.1083/jem.20111355

Toth, P., Tucsek, Z., Nosowska, D., Gautam, T., Mitschelen, M., Tarantini, S., et al. (2013). Age-related autoregulatory dysfunction and cerebrovascular injury in mice with angiotensin II-induced hypertension. *J. Cereb. Blood Flow Metab.* 33, 1732–1742. doi: 10.1038/jcbfm.2013.143

Venkatachalam, K., and Montell, C. (2007). TRP channels. *Annu. Rev. Biochem.* 76, 387–417. doi: 10.1146/annurev.biochem.75.103004.142819

Venkatachalam, K., and Montell, C. (2007). TRP channels. *Annu. Rev. Biochem.* 76, 387–417. doi: 10.1146/annurev.biochem.75.103004.142819

Verstrepen, L., Bekaert, T., Chau, T. L., Tavernier, J., Chariot, A., and Beyeart, R. (2008). TLR4-IL-1R and TNF-R signaling to NF-kappaB variations on a common theme. *Cell Mol. Life Sci.* 65, 2964–2978. doi: 10.1007/s00018-008-8064-8

Wang, H., Cheng, X., Tian, J., Xiao, Y., Tian, J., Xu, F., et al. (2020a). TRPC channels: structure, function, regulation and recent advances in small molecular probes. *Pharmacol. Ther.* 209:107497. doi: 10.1016/j.pharmthera.2020.107497

Wang, J., Zhao, M., Jia, P., Liu, F. F., Chen, K., Meng, F. Y., et al. (2020b). The analgesic action of larynx acetate, a potent TRPC6 inhibitor, in rat neuropathic pain model induced by spared nerve injury. *J. Neuroinflamm.* 17:118. doi: 10.1186/s12974-020-01767-8

Weber, E. W., Han, F., Tauseef, M., Birnbaum, L., Mehta, D., and Muller, W. A. (2015). TRPC6 is the endothelial calcium channel that regulates leukocyte

Frontiers in Cell and Developmental Biology | www.frontiersin.org 17 February 2021 | Volume 8 | Article 594283
transendothelial migration during the inflammatory response. *J. Exp. Med.* 212, 1883–1899. doi: 10.1084/jem.20150353

Wei, T., Wang, Y., Xu, W., Liu, Y., Chen, H., and Yu, Z. (2019). KCa3.1 deficiency attenuates neuroinflammation by regulating an astrocyte phenotype switch involving the PI3K/AKT/GSK3β pathway. *Neurobiol. Dis.* 132:104588. doi: 10.1016/j.nbd.2019.104588

Werner, Y., Mass, E., Ashok Kumar, P., Ulas, T., Händler, K., Horne, A., et al. (2020). Cxcr4 distinguishes HSC-derived monocytes from microglia and reveals monocyte immune responses to experimental stroke. *Nat. Neurosci.* 23, 351–362. doi: 10.1038/s41593-020-0585-y

Xie, W., Zhu, T., Dong, X., Nan, F., Meng, X., Zhou, P., et al. (2019). HMG1- triggered inflammation inhibition of notoginseng leaf triterpenes against cerebral ischemia and reperfusion injury via MAPK and NF-κB signaling pathways. *Biomolecules* 9:512. doi: 10.3390/biom9100512

Xu, N., Meng, H., Liu, T., Feng, Y., Qi, Y., and Wang, H. (2018). TRPC1 deficiency exacerbates cerebral ischemia/reperfusion-induced neurological injury by potentiating Nox4-derived reactive oxygen species generation. *Cell Physiol. Biochem.* 51, 1723–1738. doi: 10.1159/000495676

Yao, C., Zhang, J., Chen, F., and Lin, Y. (2013). Neuroprotectin D1 attenuates brain damage induced by transient middle cerebral artery occlusion in rats through TRPC6/CREB pathways. *Mol. Med. Rep.* 8, 543–550. doi: 10.3892/mmr.2013.1543

Yao, C., Zhang, J., Liu, G., Chen, F., and Lin, Y. (2014). Neuroprotection by (-)-epigallocatechin-3-gallate in a rat model of stroke is mediated through inhibition of endoplasmic reticulum stress. *Mol. Med. Rep.* 9, 69–76. doi: 10.3892/mmr.2013.1778

Ye, J., Das, S., Roy, A., Wei, W., Huang, H., Lorenz-Guertin, J. M., et al. (2019). Ischemic injury-induced CaMKIIδ and CaMKIIγ confer neuroprotection through the NF-κB signaling pathway. *Mol. Neurobiol.* 56, 2123–2136. doi: 10.1007/s12035-018-1198-2

Zhang, H., Sun, S., Wu, L., Pchitskaya, E., Zakharova, O., Fon Tacer, K., et al. (2016). Store-operated calcium channel complex in postsynaptic spines: a new therapeutic target for Alzheimer’s disease treatment. *J. Neurosci.* 36, 11837–11850. doi: 10.1523/jneurosci.1188-16.2016

Zhang, Y., Qin, W., Zhang, L., Wu, X., Du, N., Hu, Y., et al. (2015). MicroRNA-26a prevents endothelial cell apoptosis by directly targeting TRPC6 in the setting of atherosclerosis. *Sci. Rep.* 5:9401. doi: 10.1038/srep09401

Zhou, J., Du, W., Zhou, K., Tai, Y., Yao, H., Jia, Y., et al. (2008). Critical role of TRPC6 channels in the formation of excitatory synapses. *Nat. Neurosci.* 11, 741–743. doi: 10.1038/nn.2127

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Liu, Chen, Lin, Xiang, Yang, Zheng, Xiong and Zhu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.